Skip to main content
NCBI home page
Medline Book to support NIHPA logoLink to Medline Book to support NIHPA
. 2019 Dec;23(64):1–88. doi: 10.3310/hta23640

3-month versus 6-month adjuvant chemotherapy for patients with high-risk stage II and III colorectal cancer: 3-year follow-up of the SCOT non-inferiority RCT.

Timothy Iveson, Kathleen A Boyd, Rachel S Kerr, Jose Robles-Zurita, Mark P Saunders, Andrew H Briggs, Jim Cassidy, Niels Henrik Hollander, Josep Tabernero, Andrew Haydon, Bengt Glimelius, Andrea Harkin, Karen Allan, John McQueen, Sarah Pearson, Ashita Waterston, Louise Medley, Charles Wilson, Richard Ellis, Sharadah Essapen, Amandeep S Dhadda, Mark Harrison, Stephen Falk, Sherif Raouf, Charlotte Rees, Rene K Olesen, David Propper, John Bridgewater, Ashraf Azzabi, David Farrugia, Andrew Webb, David Cunningham, Tamas Hickish, Andrew Weaver, Simon Gollins, Harpreet Wasan, James Paul
PMCID: PMC6936167  PMID: 31852579

Abstract

BACKGROUND

Oxaliplatin and fluoropyrimidine chemotherapy administered over 6 months is the standard adjuvant regimen for patients with high-risk stage II or III colorectal cancer. However, the regimen is associated with cumulative toxicity, characterised by chronic and often irreversible neuropathy.

OBJECTIVES

To assess the efficacy of 3-month versus 6-month adjuvant chemotherapy for colorectal cancer and to compare the toxicity, health-related quality of life and cost-effectiveness of the durations.

DESIGN

An international, randomised, open-label, non-inferiority, Phase III, parallel-group trial.

SETTING

A total of 244 oncology clinics from six countries: UK (England, Scotland, Wales and Northern Ireland), Denmark, Spain, Sweden, Australia and New Zealand.

PARTICIPANTS

Adults aged ≥ 18 years who had undergone curative resection for high-risk stage II or III adenocarcinoma of the colon or rectum.

INTERVENTIONS

The adjuvant treatment regimen was either oxaliplatin and 5-fluorouracil or oxaliplatin and capecitabine, randomised to be administered over 3 or 6 months.

MAIN OUTCOME MEASURES

The primary outcome was disease-free survival. Overall survival, adverse events, neuropathy and health-related quality of life were also assessed. The main cost categories were chemotherapy treatment and hospitalisation. Cost-effectiveness was assessed through incremental cost comparisons and quality-adjusted life-year gains between the options and was reported as net monetary benefit using a willingness-to-pay threshold of £30,000 per quality-adjusted life-year per patient.

RESULTS

Recruitment is closed. In total, 6088 patients were randomised (3044 per group) between 27 March 2008 and 29 November 2013, with 6065 included in the intention-to-treat analyses (3-month analysis, n = 3035; 6-month analysis, n = 3030). Follow-up for the primary analysis is complete. The 3-year disease-free survival rate in the 3-month treatment group was 76.7% (standard error 0.8%) and in the 6-month treatment group was 77.1% (standard error 0.8%), equating to a hazard ratio of 1.006 (95% confidence interval 0.909 to 1.114; p-value for non-inferiority = 0.012), confirming non-inferiority for 3-month adjuvant chemotherapy. Frequent adverse events (alopecia, anaemia, anorexia, diarrhoea, fatigue, hand-foot syndrome, mucositis, sensory neuropathy, neutropenia, pain, rash, altered taste, thrombocytopenia and watery eye) showed a significant increase in grade with 6-month duration; the greatest difference was for sensory neuropathy (grade ≥ 3 was 4% for 3-month vs.16% for 6-month duration), for which a higher rate of neuropathy was seen for the 6-month treatment group from month 4 to ≥ 5 years (p < 0.001). Quality-of-life scores were better in the 3-month treatment group over months 4-6. A cost-effectiveness analysis showed 3-month treatment to cost £4881 less over the 8-year analysis period, with an incremental net monetary benefit of £7246 per patient.

CONCLUSIONS

The study achieved its primary end point, showing that 3-month oxaliplatin-containing adjuvant chemotherapy is non-inferior to 6 months of the same regimen; 3-month treatment showed a better safety profile and cost less. For future work, further follow-up will refine long-term estimates of the duration effect on disease-free survival and overall survival. The health economic analysis will be updated to include long-term extrapolation for subgroups. We expect these analyses to be available in 2019-20. The Short Course Oncology Therapy (SCOT) study translational samples may allow the identification of patients who would benefit from longer treatment based on the molecular characteristics of their disease.

TRIAL REGISTRATION

Current Controlled Trials ISRCTN59757862 and EudraCT 2007-003957-10.

FUNDING

This project was funded by the National Institute for Health Research (NIHR) Health Technology Assessment programme and will be published in full in Health Technology Assessment; Vol. 23, No. 64. See the NIHR Journals Library website for further project information. This research was supported by the Medical Research Council (transferred to NIHR Evaluation, Trials and Studies Coordinating Centre - Efficacy and Mechanism Evaluation; grant reference G0601705), the Swedish Cancer Society and Cancer Research UK Core Clinical Trials Unit Funding (funding reference C6716/A9894).

Plain language summary

Patients diagnosed with bowel cancer are likely to have surgery to remove the tumour. Patients diagnosed with a more advanced stage of the disease are then likely to be offered what is known as adjuvant chemotherapy – chemotherapy to kill any cancer cells that have already spread but cannot be seen. Adjuvant chemotherapy is usually given over 6 months using two medicines known as oxaliplatin and fluoropyrimidine. This chemotherapy has side effects of diarrhoea, nausea and vomiting, and it reduces the numbers of cells in the blood. It can also damage nerves, which causes discomfort, numbness and tingling; in some cases, this can go on for years. These side effects are more likely to develop with longer treatment. This study looked at whether or not shortening the time over which patients were given oxaliplatin and fluoropyrimidine chemotherapy reduced its effectiveness. In this large study of over 6000 patients, half of the patients were allocated by chance to be treated for 3 months and the other half to be treated for 6 months. Reducing the time that patients had chemotherapy from 6 months to 3 months did not make the treatment less effective. When patients treated with chemotherapy over 3 months were compared with those treated over 6 months, 77% of patients in both groups were well with no detectable disease 3 years after surgery. Patients were less likely to get side effects with 3-month chemotherapy. In particular, the chance of persistent long-term nerve damage was lower, resulting in patients with 3-month chemotherapy having better health-related quality of life. Overall, the study showed that 3-month adjuvant chemotherapy for patients with bowel cancer is as effective as 6-month adjuvant chemotherapy and causes fewer side effects.

Full text of this article can be found in Bookshelf.

References

  1. Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C. GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC Cancer Base No.11. Lyon: International Agency for Research on Cancer; 2013.
  2. Obrand DI, Gordon PH. Incidence and patterns of recurrence following curative resection for colorectal carcinoma. Dis Colon Rectum 1997;40:15–24. https://doi.org/10.1007/BF02055676 doi: 10.1007/BF02055676. [DOI] [PubMed]
  3. Moertel CG, Fleming TR, Macdonald JS, Haller DG, Laurie JA, Goodman PJ, et al. Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma. N Engl J Med 1990;322:352–8. https://doi.org/10.1056/NEJM199002083220602 doi: 10.1056/NEJM199002083220602. [DOI] [PubMed]
  4. O’Connell MJ, Laurie JA, Kahn M, Fitzgibbons RJ, Erlichman C, Shepherd L, et al. Prospectively randomized trial of postoperative adjuvant chemotherapy in patients with high-risk colon cancer. J Clin Oncol 1998;16:295–300. https://doi.org/10.1200/JCO.1998.16.1.295 doi: 10.1200/JCO.1998.16.1.295. [DOI] [PubMed]
  5. National Comprehensive Cancer Network (NCCN). Guidelines: Colon Cancer (Version 2.2107). Plymouth Meeting, PA: NCCN.
  6. André T, Boni C, Mounedji-Boudiaf L, Navarro M, Tabernero J, Hickish T, et al. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 2004;350:2343–51. https://doi.org/10.1056/NEJMoa032709 doi: 10.1056/NEJMoa032709. [DOI] [PubMed]
  7. Kuebler JP, Wieand HS, O’Connell MJ, Smith RE, Colangelo LH, Yothers G, et al. Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: results from NSABP C-07. J Clin Oncol 2007;25:2198–204. https://doi.org/10.1200/JCO.2006.08.2974 doi: 10.1200/JCO.2006.08.2974. [DOI] [PubMed]
  8. Haller DG, Tabernero J, Maroun J, de Braud F, Price T, Van Cutsem E, et al. Capecitabine plus oxaliplatin compared with fluorouracil and folinic acid as adjuvant therapy for stage III colon cancer. J Clin Oncol 2011;29:1465–71. https://doi.org/10.1200/JCO.2010.33.6297 doi: 10.1200/JCO.2010.33.6297. [DOI] [PubMed]
  9. Schmoll HJ, Van Cutsem E, Stein A, Valentini V, Glimelius B, Haustermans K, et al. ESMO Consensus Guidelines for management of patients with colon and rectal cancer. A personalized approach to clinical decision making. Ann Oncol 2012;23:2479–516. https://doi.org/10.1093/annonc/mds236 doi: 10.1093/annonc/mds236. [DOI] [PubMed]
  10. Land SR, Kopec JA, Cecchini RS, Ganz PA, Wieand HS, Colangelo LH, et al. Neurotoxicity from oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: NSABP C-07. J Clin Oncol 2007;25:2205–11. https://doi.org/10.1200/JCO.2006.08.6652 doi: 10.1200/JCO.2006.08.6652. [DOI] [PubMed]
  11. Pachman DR, Qin R, Seisler DK, Smith EM, Beutler AS, Ta LE, et al. Clinical course of oxaliplatin-induced neuropathy: results from the randomized phase III trial N08CB (Alliance). J Clin Oncol 2015;33:3416–22. https://doi.org/10.1200/JCO.2014.58.8533 doi: 10.1200/JCO.2014.58.8533. [DOI] [PMC free article] [PubMed]
  12. Saini A, Norman AR, Cunningham D, Chau I, Hill M, Tait D, et al. Twelve weeks of protracted venous infusion of fluorouracil (5-FU) is as effective as 6 months of bolus 5-FU and folinic acid as adjuvant treatment in colorectal cancer. Br J Cancer 2003;88:1859–65. https://doi.org/10.1038/sj.bjc.6600995 doi: 10.1038/sj.bjc.6600995. [DOI] [PMC free article] [PubMed]
  13. Laudicella M, Walsh B, Burns E, Smith PC. Cost of care for cancer patients in England: evidence from population-based patient-level data. Br J Cancer 2016;114:1286–92. https://doi.org/10.1038/bjc.2016.77 doi: 10.1038/bjc.2016.77. [DOI] [PMC free article] [PubMed]
  14. André T, Iveson T, Labianca R, Meyerhardt JA, Souglakos I, Yoshino T, et al. The IDEA (International Duration Evaluation of Adjuvant Chemotherapy) collaboration: prospective combined analysis of phase III trials investigating duration of adjuvant therapy with the FOLFOX (FOLFOX4 or Modified FOLFOX6) or XELOX (3 versus 6 months) regimen for patients with stage III colon cancer: trial design and current status. Curr Colorectal Cancer Rep 2013;9:261–9. https://doi.org/10.1007/s11888-013-0181-6 doi: 10.1007/s11888-013-0181-6. [DOI] [PMC free article] [PubMed]
  15. World Medical Association. World Medical Association Declaration of Helsinki. Ethical principles for medical research involving human subjects. Bull World Health Organ 2001;79:373–4. [PMC free article] [PubMed]
  16. Iveson TJ, Kerr RS, Saunders MP, Cassidy J, Hollander NH, Tabernero J, et al. 3 versus 6 months of adjuvant oxaliplatin-fluoropyrimidine combination therapy for colorectal cancer (SCOT): an international, randomised, phase 3, non-inferiority trial. Lancet Oncol 2018;19:562–78. https://doi.org/10.1016/S1470-2045(18)30093-7 doi: 10.1016/S1470-2045(18)30093-7. [DOI] [PMC free article] [PubMed]
  17. Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 1993;85:365–76. https://doi.org/10.1093/jnci/85.5.365 doi: 10.1093/jnci/85.5.365. [DOI] [PubMed]
  18. Whistance RN, Conroy T, Chie W, Costantini A, Sezer O, Koller M, et al. Clinical and psychometric validation of the EORTC QLQ-CR29 questionnaire module to assess health-related quality of life in patients with colorectal cancer. Eur J Cancer 2009;45:3017–26. https://doi.org/10.1016/j.ejca.2009.08.014 doi: 10.1016/j.ejca.2009.08.014. [DOI] [PubMed]
  19. Rabin R, de Charro F. EQ-5D: a measure of health status from the EuroQol Group. Ann Med 2001;33:337–43. https://doi.org/10.3109/07853890109002087 doi: 10.3109/07853890109002087. [DOI] [PubMed]
  20. Dolan P. Modeling valuations for EuroQol health states. Med Care 1997;35:1095–108. https://doi.org/10.1097/00005650-199711000-00002 doi: 10.1097/00005650-199711000-00002. [DOI] [PubMed]
  21. Huang HQ, Brady MF, Cella D, Fleming G. Validation and reduction of FACT/GOG-Ntx subscale for platinum/paclitaxel-induced neurologic symptoms: a gynecologic oncology group study. Int J Gynecol Cancer 2007;17:387–93. https://doi.org/10.1111/j.1525-1438.2007.00794.x doi: 10.1111/j.1525-1438.2007.00794.x. [DOI] [PubMed]
  22. Osoba D, Rodrigues G, Myles J, Zee B, Pater J. Interpreting the significance of changes in health-related quality-of-life scores. J Clin Oncol 1998;16:139–44. https://doi.org/10.1200/JCO.1998.16.1.139 doi: 10.1200/JCO.1998.16.1.139. [DOI] [PubMed]
  23. Pickard AS, Neary MP, Cella D. Estimation of minimally important differences in EQ-5D utility and VAS scores in cancer. Health Qual Life Outcomes 2007;5:70. https://doi.org/10.1186/1477-7525-5-70 doi: 10.1186/1477-7525-5-70. [DOI] [PMC free article] [PubMed]
  24. Paul J, Iveson T, Midgley R, Harkin A, Masterton M, Alexander L, Cassidy J. Choice of randomisation time-point in non-inferiority studies of reduced treatment duration: experience from the SCOT study. Trials 2011;12:A30. https://doi.org/10.1186/1745-6215-12-S1-A30 doi: 10.1186/1745-6215-12-S1-A30. [DOI]
  25. Rubin DB. Multiple Imputation for Nonresponse in Surveys. New York, NY: John Wiley & Sons; 1987. https://doi.org/10.1002/9780470316696 doi: 10.1002/9780470316696. [DOI]
  26. Qian W, Parmar MK, Sambrook RJ, Fayers PM, Girling DJ, Stephens RJ. Analysis of messy longitudinal data from a randomized clinical trial. MRC Lung Cancer Working Party. Stat Med 2000;19:2657–74. https://doi.org/10.1002/1097-0258(20001015)19:19<2657::AID-SIM557>3.0.CO;2-3 doi: 10.1002/1097-0258(20001015)19:19&#x0003c;2657::AID-SIM557&#x0003e;3.0.CO;2-3. [DOI] [PubMed]
  27. Hochberg Y. A sharper Bonferroni procedure for multiple tests of significance. Biometrika 1988;75:800–2. https://doi.org/10.1093/biomet/75.4.800 doi: 10.1093/biomet/75.4.800. [DOI]
  28. Demets DL. Futility approaches to interim monitoring by data monitoring committees. Clin Trials 2006;3:522–9. https://doi.org/10.1177/1740774506073115 doi: 10.1177/1740774506073115. [DOI] [PubMed]
  29. André T, de Gramont A, Vernerey D, Chibaudel B, Bonnetain F, Tijeras-Raballand A, et al. Adjuvant fluorouracil, leucovorin, and oxaliplatin in stage II to III colon cancer: updated 10-year survival and outcomes according to BRAF mutation and mismatch repair status of the MOSAIC study. J Clin Oncol 2015;33:4176–87. https://doi.org/10.1200/JCO.2015.63.4238 doi: 10.1200/JCO.2015.63.4238. [DOI] [PubMed]
  30. National Institute for Health and Care Excellence (NICE). Guide to the Methods of Technology Appraisal. London: NICE; 2013. [PubMed]
  31. Petrou S, Gray A. Economic evaluation alongside randomised controlled trials: design, conduct, analysis, and reporting. BMJ 2011;342:d1548. https://doi.org/10.1136/bmj.d1548 doi: 10.1136/bmj.d1548. [DOI] [PMC free article] [PubMed]
  32. Billingham LJ, Abrams KR. Simultaneous analysis of quality of life and survival data. Stat Methods Med Res 2002;11:25–48. https://doi.org/10.1191/0962280202sm269ra doi: 10.1191/0962280202sm269ra. [DOI] [PubMed]
  33. Boyd KA, Briggs AH, Paul J, Iveson T, Midgely R, Harkin A, et al. Analysis of adverse events and health-related quality of life data for an economic evaluation of adjuvant chemotherapy incolorectal cancer: when can we stop collecting? Trials 2011;12:A41. https://doi.org/10.1186/1745-6215-12-S1-A41 doi: 10.1186/1745-6215-12-S1-A41. [DOI]
  34. Billingham LJ, Abrams KR, Jones DR. Methods for the analysis of quality-of-life and survival data in health technology assessment. Health Technol Assess 1999;3(10). https://doi.org/10.3310/hta3100 doi: 10.3310/hta3100. [DOI] [PubMed]
  35. Joint Formulary Committee. British National Formulary 73 ed. London: BMJ Group and Pharmaceutical Press; 2017.
  36. Wong YN, Meropol NJ, Speier W, Sargent D, Goldberg RM, Beck JR. Cost implications of new treatments for advanced colorectal cancer. Cancer 2009;115:2081–91. https://doi.org/10.1002/cncr.24246 doi: 10.1002/cncr.24246. [DOI] [PMC free article] [PubMed]
  37. NHS National Services Scotland Information Services Division. Scottish Health Service Costs 2016. Edinburgh: NHS National Services Scotland Information Services Division; 2016.
  38. Lin DY, Feuer EJ, Etzioni R, Wax Y. Estimating medical costs from incomplete follow-up data. Biometrics 1997;53:419–34. https://doi.org/10.2307/2533947 doi: 10.2307/2533947. [DOI] [PubMed]
  39. Husereau D, Drummond M, Petrou S, Carswell C, Moher D, Greenberg D, et al. Consolidated Health Economic Evaluation Reporting Standards (CHEERS) – explanation and elaboration: a report of the ISPOR health economic evaluation publication guidelines good reporting practices task force. Value Health 2013;16:231–50. https://doi.org/10.1016/j.jval.2013.02.002 doi: 10.1016/j.jval.2013.02.002. [DOI] [PubMed]
  40. Briggs AH, Wonderling DE, Mooney CZ. Pulling cost-effectiveness analysis up by its bootstraps: a non-parametric approach to confidence interval estimation. Health Econ 1997;6:327–40. https://doi.org/10.1002/(SICI)1099-1050(199707)6:4<327::AID-HEC282>3.0.CO;2-W doi: 10.1002/(SICI)1099-1050(199707)6:4&#x0003c;327::AID-HEC282&#x0003e;3.0.CO;2-W. [DOI] [PubMed]
  41. Fenwick E, Claxton K, Sculpher M. Representing uncertainty: the role of cost-effectiveness acceptability curves. Health Econ 2001;10:779–87. https://doi.org/10.1002/hec.635 doi: 10.1002/hec.635. [DOI] [PubMed]
  42. Tournigand C, André T, Bonnetain F, Chibaudel B, Lledo G, Hickish T, et al. Adjuvant therapy with fluorouracil and oxaliplatin in stage II and elderly patients (between ages 70 and 75 years) with colon cancer: subgroup analyses of the Multicenter International Study of Oxaliplatin, Fluorouracil, and Leucovorin in the Adjuvant Treatment of Colon Cancer trial. J Clin Oncol 2012;30:3353–60. https://doi.org/10.1200/JCO.2012.42.5645 doi: 10.1200/JCO.2012.42.5645. [DOI] [PubMed]
  43. Sargent DJ, Marsoni S, Monges G, Thibodeau SN, Labianca R, Hamilton SR, et al. Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer. J Clin Oncol 2010;28:3219–26. https://doi.org/10.1200/JCO.2009.27.1825 doi: 10.1200/JCO.2009.27.1825. [DOI] [PMC free article] [PubMed]
  44. Shi Q, Sobrero AF, Shields AF, Yoshino T, Paul J, Taieb J, et al. Prospective pooled analysis of six phase III trials investigating duration of adjuvant oxaliplatin-based therapy (3 vs 6 months) for patients with stage III colon cancer: the IDEA (International Duration Evaluation of Adjuvant chemotherapy) collaboration. J Clin Oncol 2017;35:LBA1. https://doi.org/10.1200/JCO.2017.35.15_suppl.LBA1 doi: 10.1200/JCO.2017.35.15_suppl.LBA1. [DOI]
  45. Chau I, Norman AR, Cunningham D, Tait D, Ross PJ, Iveson T, et al. A randomised comparison between 6 months of bolus fluorouracil/leucovorin and 12 weeks of protracted venous infusion fluorouracil as adjuvant treatment in colorectal cancer. Ann Oncol 2005;16:549–57. https://doi.org/10.1093/annonc/mdi116 doi: 10.1093/annonc/mdi116. [DOI] [PubMed]
  46. Twelves C, Wong A, Nowacki MP, Abt M, Burris H, Carrato A, et al. Capecitabine as adjuvant treatment for stage III colon cancer. N Engl J Med 2005;352:2696–704. https://doi.org/10.1056/NEJMoa043116 doi: 10.1056/NEJMoa043116. [DOI] [PubMed]
  47. Schmoll HJ, Cartwright T, Tabernero J, Nowacki MP, Figer A, Maroun J, et al. Phase III trial of capecitabine plus oxaliplatin as adjuvant therapy for stage III colon cancer: a planned safety analysis in 1,864 patients. J Clin Oncol 2007;25:102–9. https://doi.org/10.1200/JCO.2006.08.1075 doi: 10.1200/JCO.2006.08.1075. [DOI] [PubMed]
  48. Postma TJ, Aaronson NK, Heimans JJ, Muller MJ, Hildebrand JG, Delattre JY, et al. The development of an EORTC quality of life questionnaire to assess chemotherapy-induced peripheral neuropathy: the QLQ-CIPN20. Eur J Cancer 2005;41:1135–9. doi: 10.1016/j.ejca.2005.02.012. [DOI] [PubMed]
  49. Majithia N, Temkin SM, Ruddy KJ, Beutler AS, Hershman DL, Loprinzi CL. National Cancer Institute-supported chemotherapy-induced peripheral neuropathy trials: outcomes and lessons. Support Care Cancer 2016;24:1439–47. https://doi.org/10.1007/s00520-015-3063-4 doi: 10.1007/s00520-015-3063-4. [DOI] [PMC free article] [PubMed]
  50. Mols F, Beijers T, Lemmens V, van den Hurk CJ, Vreugdenhil G, van de Poll-Franse LV. Chemotherapy-induced neuropathy and its association with quality of life among 2- to 11-year colorectal cancer survivors: results from the population-based PROFILES registry. J Clin Oncol 2013;31:2699–707. https://doi.org/10.1200/JCO.2013.49.1514 doi: 10.1200/JCO.2013.49.1514. [DOI] [PubMed]
  51. Sobrero A, Lonardi S, Rosati G, Di Bartolomeo M, Ronzoni M, Pella N, et al. FOLFOX or CAPOX in stage II to III colon cancer: Efficacy Results of the Italian Three or Six Colon Adjuvant Trial. J Clin Oncol 2018;36:1478–85. https://doi.org/10.1200/JCO.2017.76.2187 doi: 10.1200/JCO.2017.76.2187. [DOI] [PubMed]
  52. André T, Vernerey D, Mineur L, Bennouna J, Desrame J, Faroux R, et al. Three versus 6 months of oxaliplatin-based adjuvant chemotherapy for patients with stage III colon cancer: disease-free survival results from a randomized, open-label, International Duration Evaluation of Adjuvant (IDEA) France, Phase III Trial. J Clin Oncol 2018;36:1469–77. https://doi.org/10.1200/JCO.2017.76.0355 doi: 10.1200/JCO.2017.76.0355. [DOI] [PubMed]
  53. Yoshino T, Yamanaka T, Oki E, Kotaka M, Manaka D, Eto T, et al. Efficacy and long-term peripheral sensory neuropathy of 3 vs 6 months of oxaliplatin-based adjuvant chemotherapy for colon cancer: The ACHIEVE Phase 3 Randomized Clinical Trial [published online ahead of print September 12 2019]. JAMA Oncol 2019. https://doi.org/10.1001/jamaoncol.2019.2572 doi: 10.1001/jamaoncol.2019.2572. [DOI] [PMC free article] [PubMed]
  54. Souglakos J, Boukovinas I, Kakolyris S, Xynogalos S, Ziras N, Athanasiadis A, et al. Three versus six months adjuvant FOLFOX or CAPOX for high risk stage II and stage III colon cancer patients: the efficacy results of Hellenic Oncology Research Group (HORG) participation to the International Duration Evaluation of Adjuvant chemotherapy (IDEA) project [published online ahead of print June 22 2019]. Ann Oncol 2019. https://doi.org/10.1093/annonc/mdz193 doi: 10.1093/annonc/mdz193. [DOI] [PubMed]
  55. Grothey A, Sobrero AF, Shields AF, Yoshino T, Paul J, Taieb J, et al. Duration of adjuvant chemotherapy for stage III colon cancer. N Engl J Med 2018;378:1177–88. https://doi.org/10.1056/NEJMoa1713709 doi: 10.1056/NEJMoa1713709. [DOI] [PMC free article] [PubMed]
  56. Hooper R. The Bayesian interpretation of a P-value depends only weakly on statistical power in realistic situations. J Clin Epidemiol 2009;62:1242–7. https://doi.org/10.1016/j.jclinepi.2009.02.004 doi: 10.1016/j.jclinepi.2009.02.004. [DOI] [PubMed]

RESOURCES